Delayed Drug Effects. Distribution to Effect Site. Physiological Intermediate

Similar documents
1. Immediate 2. Delayed 3. Cumulative

Pharmacodynamics. Delayed Drug Effects. Delayed and Cumulative Effects

Volume of Distribution. Objectives. Volume of Distribution

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Clinical Pharmacology. Pharmacodynamics the next step. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

Target Concentration Intervention

Understand the physiological determinants of extent and rate of absorption

PKPD. Workshop. Warfarin Data. What does this mean? Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

PKPD. Workshop. Warfarin Data. What does this mean? Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

Mousa Suboh. Osama Alzoubi (OZ) Malik Zuhlof. 1 P a g e

Basic Concepts of TDM

Clinical Pharmacology. Clinical Pharmacology = Disease Progress + Drug Action. Outline. Disease Progress and Drug Action

Chapter 1 Introduction

Pharmacodynamic principles and the time course of immediate drug effects

Time to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect

Pharmacokinetics of drug infusions

Principles of Pharmacokinetics

Environmental Variability

CLINICAL TRIAL SIMULATION & ANALYSIS

Disease Progress. Clinical Pharmacology = Disease Progress + Drug Action. Outline. Parkinson s Disease. Interpretation of ELLDOPA

Pharmacokinetic Phase

Drug Receptor Interactions and Pharmacodynamics

Children are small adults and babies are young children

The time of maximum effect for model selection in pharmacokinetic pharmacodynamic analysis applied to frusemide

Primary Exam Physiology lecture 5. Haemostasis

NOACS/DOACS*: COAGULATION TESTS

What are blood clots?

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )

Quetiapine Case 1 Warfarin Jose de Leon, MD

The Time Course of Placebo Response in Clinical Trials

Basic pharmacokinetics. Frédérique Servin APHP hôpital Bichat Paris, FRANCE

Basics of Pharmacology

Platelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment

Vitamin K1 metabolism in relation to pharmacodynamic

Pharmacokinetics of propofol when given by intravenous

Nonlinear Pharmacokinetics

DRUG DISTRIBUTION. Distribution Blood Brain Barrier Protein Binding

NEW MK-7 SELECT INTRODUCTION

UNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.

TDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Pharmacokinetics Applied to the Treatment of Asthma

ADVANCES IN ANTICOAGULATION

Review of Neurochemistry What are neurotransmitters?

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Angina Pectoris Dr. Shariq Syed

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Vitamin K. Amina Ziyad Elaf Sohaib

Pharmacology - Problem Drill 11: Vasoactive Agents

Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring

Osnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,

Pharmacokinetics I. Dr. M.Mothilal Assistant professor

Anticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics

Appendix 3 PCC Warfarin Reversal

ACTIVE TRANSPORT OF SALICYLATE BY RAT JEJUNUM

PHA Case Studies V (Answers)

Pharmacokinetic Calculations

Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin

Lippincott Questions Pharmacology

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

Pharmacokinetics. Inhalational Agents. Uptake and Distribution

Blood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.

Pharmacokinetics Overview

Drug-Disease Modeling Applied to Drug Development and Regulatory Decision Making in the Type 2 Diabetes Mellitus Arena

Therefore, there is a strong interaction between pharmacodynamics and pharmacokinetics

Beta-blockers. Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol.

Pharmacokinetic Phase

Heart Failure (HF) Treatment

Anticoagulants: Agents, Pharmacology and Reversal

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

Scaling Renal Function in Neonates and Infants to Describe the Pharmacodynamics of Antibiotic Nephrotoxicity

Perioperative risk reduction and B-blockers. Topics. Introduction 3/26/2012

The importance of clearance

Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology

Topic 1: Lifestyle, Health and Risk

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Adrenergic agonists Sympathomimetic drugs. ANS Pharmacology Lecture 4 Dr. Hiwa K. Saaed College of Pharmacy/University of Sulaimani

New Horizons in Anticoagulation: The Way of the Future. Disclosure. Outline. The speaker has nothing to disclose in relation to this presentation

Local Anesthetics. Xiaoping Du Room E417 MSB Department of Pharmacology Phone (312) ;

Discussion. Dr Venu 2 nd year, General medicine

Richard A. Beers, M.D. Professor, Anesthesiology SUNY Upstate Medical Univ VA Medical Center Syracuse, NY

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

A primer on pharmacology

PKPD Changes with Age

4. Amiodarone Background. 4. Amiodarone

Part IV Antithrombotics, Anticoagulants and Fibrinolytics

Pharmacology of intravenous induction agents

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHARMACODYNAMICS II QUANTITATIVE ASPECTS OF DRUGS. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

General Principles of Pharmacology and Toxicology

ANTI - ARRHYTHMIC DRUGS

Appendix IV - Prescribing Guidance for Apixaban

Pharmacogenomics-based individualization of drug therapy

CLOSED-LOOP FEEDBACK CONTROL OF PROPOFOL ANAESTHESIA BY QUANTITATIVE EEG ANALYSIS IN HUMANS

MANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

Population Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development. Leon Aarons Manchester Pharmacy School University of Manchester

Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES

Transcription:

1 Pharmacodynamics Delayed Drug Effects In reality all drug effects are delayed in relation to plasma drug concentrations. Some drug actions e.g. anti-thrombin III binding and inhibition of Factor Xa by heparin have negligible delay because the drug site of action is in the plasma itself. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand 2 Objectives Distinguish drug action, effect and response Describe the difference between pharmacokinetic and physiokinetic models for delayed drug response Be able to describe the reasons for delayed response to thiopentone and warfarin Understand why drug responses can be markedly delayed and appear to have little relationship to elimination half-life 3 Delayed Drug Effects Distribution to Effect Site» pharmaco-kinetics Physiological Intermediate» physio-kinetics Delayed drug effects are usually due to both of these mechanisms. It takes time for drug to distribute to the site of action and then it takes time for the drug action to change physiological intermediate substances before the drug response is observed. While it is possible sometimes to distinguish both mechanisms it is most common to identify only one delay process. If the delays are short (minutes) then the mechanism is probably a distribution process whereas if the delay is long (hours or longer) then the mechanism is more likely to be physiological.

4 Terminology Drug Action» on a receptor Drug Effect» receptor mediated change in a physiological intermediate Drug Response» observed consequence of physiological intermediate It can be helpful when dealing with delayed drug effects to use a special set of words to describe what a drug is doing. The first step is for a drug to have it s action at a receptor. This is at it s site of action and reflects the instantaneous consequences of the drug at it s binding site. Binding may be to a receptor e.g. a beta agonist binding to an adrenoceptor in the lung. Other sites of action include an enzyme, a transporter, an ion channel, etc. Drug delays due to distribution take place before the drug action. Physiological changes e.g. production of cyclic AMP, then lead to a drug effect e.g. bronchial smooth muscle relaxation. The effect of a drug is the observable consequence of the drug action and is usually delayed as a consequence of the turnover of one or more physiological mediators. Finally a drug response is observed e.g. increased airway peak flow in an asthmatic. There may be additional delays due to other physiological interactions and feedback mechanisms. 5 Distribution to Effect Site Effect site not in central compartment» heart digoxin increases contractility Distributional delays are readily understand in terms of anatomy. It takes time for a drug molecule to get from the blood to a target tissue because of delays in perfusion of tissues and diffusion across blood vessel walls and through extracellular spaces. The rapidly mixing central blood volume is the driving force compartment for the delivery of drug to the tissues.» brain thiopentone anaesthetic

6 Plasma Cp 0.7 x Vd/Cl Effect Compartment Effect T 1/2,eq = Equilibration Ce Half-Life T 1/2,eq Because it is usually difficult or impossible to measure drug concentration at the site of action the time course of distribution can be described empirically by proposing an effect compartment. The time course of observed drug effect is then used to deduce the time course of drug concentration at the site of action. The simplest model for an effect compartment is very similar to a one compartment model for pharmacokinetics. The time needed to reach steady state in a pharmacokinetic system receiving a constant rate input is determined by the elimination half-life from the plasma compartment. If drug concentrations in the plasma are constant then the rate of input to the effect compartment will also be constant and the time to steady state in the effect compartment will be simply determined by the equilibration half-life. More complex pharmacokinetic systems are readily described by the effect compartment model in the same way that plasma concentrations from complex inputs can be predicted with a pharmacokinetic model. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to D-tubocurarine. Clin Pharmacol Ther. 1979;25(3):358-71. 7 Equilibration Half-Life Determined by» Volume of effect compartment Organ size Tissue binding» Clearance of effect compartment Blood flow Diffusion The effect compartment half-life is also known as the equilibration half-life. The elimination half-life of a pharmacokinetic system is determined by the volume of distribution and clearance. The same factors affect the equilibration half-life Dutta S, Matsumoto Y, Muramatsu A, Matsumoto M, Fukuoka M, Ebling WF. Steady-state propofol brain:plasma and brain:blood partition coefficients and the effect-site equilibration paradox. Br J Anaesth. 1998;81(3):422-4.

8 Digoxin Time Course Ce Effect Ct Cp Cp Ct Ce Effect The time course of digoxin concentration in plasma (Cp) can be used to predict the average concentration in all the other tissues of the body (Ct). Note that Ct is not specific for any particular organ or tissue so it is not likely to reflect the distribution and equilibration at the site of action. This figure shows the time course of concentration in an effect compartment that describes the delayed increase in cardiac contractility produced by digoxin. The effect compartment reaches a peak before the average tissue concentration in part because of the more rapid perfusion of the heart compared with other tissues such as fat. A more physiological explanation for delayed effects of digoxin comes from considering the slow equilibration of binding to NaKATPase. Weiss M, Kang W. Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding. Pharm Res. 2004;21(2):231-6. 9 Digoxin Volume» extensive binding in heart to Na + K + ATPase Clearance» rapid perfusion of heart Despite rapid perfusion of the heart the equilibration half-life of digoxin is quite slow. This may be because extensive binding of digoxin to Na+K+ATPase in the heart makes the apparent volume of distribution large. Equilibration Half-life = 3 h

10 Thiopentone Time Course Thiopentone is used for the rapid induction of anaesthesia. This figure shows the time course of measured thiopentone concentrations (black symbols) compared with the effect of thiopentone on the EEG. Thiopentone slows the frequency of EEG electrical activity (right hand axis scale). The EEG scale is inverted so that slowing of the EEG causes the EEG curve to move up and down in parallel with plasma concentration. Note however the delay in the EEG curve in relation to plasma concentration. Stanski DR, Maitre PO. Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited. Anesthesiology. 1990; 72(3):412-22. 11 Thiopentone Volume» limited binding to GABA? receptors Clearance» rapid perfusion of brain Thiopentone reaches the brain quickly and is washed out rapidly because of the high blood flow to the brain. It is the rapid washout of thiopentone that leads to a short equilibration half-life of about a minute. Equilibration Half-life = 1 min 12 Physiological Intermediate Drug Action» inhibition of Vit K recycling Drug Effect» decreased synthesis of clotting factors Drug Response» prolonged coagulation time (INR) Warfarin is an anticoagulant used to treat conditions such as deep vein thrombosis or to prevent blood clots and emboli associated with atrial fibrillation. It acts by inhibiting the recycling of Vitamin K in the liver. The effect of reduced Vitamin K is a decrease in the synthesis rate of clotting factors. The observable response is an increase in the time taken for blood to clot e.g. as measured by the international normalized ratio (INR). INR=International Normalised Ratio

13 The Vitamin K Cycle Vitamin K is an essential co-factor for the synthesis of clotting factors. When the prothrombin complex precursors are activated by gamma-glutamyl decarboxylase Vitamin K is inactivated and forms Vitamin K epoxide. The action of warfarin is rapid. Warfarin is absorbed quickly from the gut and reaches the liver where it enters the cells and inhibits Vitamin K reductase and Vitamin K epoxide reductase. This stops the re-cycling of Vitamin K epoxide back to the active Vitamin K form and prothrombin complex synthesis is reduced. Sheiner LB. Computer-aided long-term anticoagulation therapy. Comput Biomed Res. 1969;2(6):507-18. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet. 1986;11:483-504. 14 mg/l Warfarin Time Course IC50=0.75 IC50=1.5 Cp=1.5 IC50=3.0 INR The time course of change in prothrombin complex is determined by the half-life of the proteins e.g. Factor VII, which are involved in blood coagulation. The slow elimination of the prothrombin complex clotting factors eventually leads to a new steady state with an associated change in INR. This figure illustrates the INR response to a loading dose and maintenance dose of warfarin. The average concentration of warfarin is 1.5 mg/l which is close to the IC50 for warfarin inhibition of Vitamin K recycling. The IC50 is like the EC50 but refers to an inhibitory drug action. 3 INR profiles are shown with different IC50 values. The steady state INR is higher when the IC50 is low and the INR is lower when the IC50 is high. However, the time to reach a new steady state INR is not affected by the IC50 because it is only determined by the half-life of the clotting factors.

15 Warfarin Delayed Response The prothrombin complex of clotting factors has an average elimination half-life of about 14 hours. This means it typically takes 2 to 3 days to reach a new steady state INR value. IC50 for synthesis is 1.5 mg/l» Synthesis is reduced 50% at the IC50» [prothrombin complex] is reduced 50% Critical parameter is» Half-life of prothrombin complex» about 14 h Takes 4 half-lives to reach SS» 2 to 3 days 16 Warfarin Dosing Target Conc is 1.5 mg/l (IC50) The target concentration for warfarin is the same as it s IC50. This leads to a 50% reduction in synthesis and a doubling of the INR. The loading dose and maintenance dose can be calculated using typical values for warfarin volume of distribution and clearance. Loading Dose» LD= 1.5 mg/l x 10 L = 15 mg Maintenance Dose» MD= 1.5 mg/l x 3 L/d = 5 mg/day 17 Warfarin Dose Adjustment Measure INR daily Wait at least 2 days before changing dose Because of the long half-life of warfarin it is always helpful to use a loading dose to reach the target concentration more quickly. However, it also takes 2 days after reaching the new warfarin steady state before the INR steady state is reached. This means that dose adjustments of warfarin must be based on INR measurements made at least 2 days previously. Warfarin takes 7 days to reach a new steady state

18 Physiological Intermediate Angiotensin Converting Enzyme Inhibitors (enalapril)» Delayed effect on blood pressure (1 week)» Half-life of Na + is about 2 days Anti-Depressants (amitriptyline)» Delayed effect on depression (2 weeks)» Unidentified mediator» A protein with a 4 day half-life? Other examples of drug with delayed responses due to physiological intermediates are shown. The physiological mediators of the blood pressure fall due to angiotensin converting enzyme inhibition are angiotensin (rapid effect) and sodium (slow effect). It can take at least a week to see the full blood pressure lowering effect because of the long half-life of sodium. Anti-depressants are commonly said to take 2 weeks to reach full effect. This can be explained by the turnover of a mediator with an half-life of several days. This is much slower than the change in synaptic amine concentrations produced by the action of these drugs on amine transporters. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994;56(4):406-19.